Table 4.
Therapeutic agents for combinatorial therapy targeting the immune check point Programmed death 1 (PD-1) and angiogenesis in interventional clinical trials currently recruiting or not yet recruiting. Data acquired from the U.S. National library of medicine (http://clinicaltrials.gov, accessed on 16 January 2019).
| Therapeutic Strategy | Cancer Type | Phase | Clinical Trial Reference |
|---|---|---|---|
| HLX10 (anti-PD-1 1) + HLX04 (anti-VEGF 2) | Solid tumor | 1 | NCT03757936 |
| SHR-1210 (anti-PD-1) with Bevacizumab (anti-VEGFR) | Gastric and hepatocellular cancer | 1/2 | NCT02942329 |
| Atezolizumab (anti-PD-L1) with Bevacizumab (anti-VEGF) | Digestive, respiratory and intrathoracic organs tumors | 2 | NCT03074513 |
| Atezolizumab (PD-L1 inhibitor), Bevacizumab (anti-VEGF) and Cobimetinib (MEK 3 inhibitor) | Ovarian and fallopian tube cancer and peritoneal carcinoma | 2 | NCT03363867 |
| PLD 4 with Atezolizumab (PD-L1 inhibitor) vs. PLD with Bevacizumab (anti-VEGF) and Atezolizumab vs. PLD with Bevacizumab | Ovarian, fallopian tube and peritoneal carcinoma | 2/3 | NCT02839707 |
| Sintilimab (anti-PD-1) with IBI305 (anti-VEGF), Pemetrexed and Cisplatin vs. Sintilimab with IBI305 and Pemetrexed vs. Pemetrexed and Cisplatin | Non-squamous non-small cell lung cancer | 3 | NCT03802240 |
| Bevacizumab (anti-VEGF) with Carboplatin and Pemetrexed vs. Bevacizumab with Atezolizumab (anti-PD-1), Carboplatin and Pemetrexed | Pleural mesothelioma malignant advanced | 3 | NCT03762018 |
1 PD-1, Programmed death receptor 1; 2 VEGF, Vascular endothelial growth factor; 3 MEK, Mitogen-activated protein kinase (involved in cancer cells proliferation); 4 PLD, Pegylated liposomal doxorubicin hydrochloride.